Identification of a new SYT2 variant validates an unusual distal motor neuropathy phenotype

Nataly I. Montes-Chinea, MD, Zhuo Guan, PhD, Marcella Coutts, MD, Cecilia Vidal, MD, Steve Courel, BS, Adriana P. Rebelo, PhD, Lisa Abreu, MPH, Stephan Zuchner, MD, PhD, J. Troy Littleton, PhD, and Mario A. Saporta, MD, PhD

Neurol Genet 2018;4:e282. doi:10.1212/NXG.0000000000000282

Abstract

Objective
To report a new SYT2 missense mutation causing distal hereditary motor neuropathy and presynaptic neuromuscular junction (NMJ) transmission dysfunction.

Methods
We report a multigenerational family with a new missense mutation, c. 1112T>A (p. Ile371-Lys), in the C2B domain of SYT2, describe the clinical and electrophysiologic phenotype associated with this variant, and validate its pathogenicity in a Drosophila model.

Results
Both proband and her mother present a similar clinical phenotype characterized by a slowly progressive, predominantly motor neuropathy and clear evidence of presynaptic NMJ dysfunction on nerve conduction studies. Validation of this new variant was accomplished by characterization of the mutation homologous to the human c. 1112T>A variant in Drosophila, confirming its dominant-negative effect on neurotransmitter release.

Conclusions
This report provides further confirmation of the role of SYT2 in human disease and corroborates the resultant unique clinical phenotype consistent with hereditary distal motor neuropathy. SYT2-related motor neuropathy is a rare disease but should be suspected in patients presenting with a combination of presynaptic NMJ dysfunction (resembling Lambert-Eaton myasthenic syndrome) and a predominantly motor neuropathy, especially in the context of a positive family history.
Glossary

ADM = abductor digiti minimi; AH = abductor hallucis; ANOVA = analysis of variance; APB = abductor pollicis brevis; CMT = Charcot-Marie-Tooth; CMTNS = Charcot-Marie-Tooth Neuropathy Score; dHMN = Hereditary distal motor neuropathy; eEJC = excitatory evoked junctional current; NMJ = neuromuscular junction; RNS = repetitive nerve stimulation; WT = wildtype.

Hereditary distal motor neuropathies (dHMNs) are a group of rare diseases that share the common feature of a length-dependent predominantly motor neuropathy.1,2 A particular type of dHMN associated with presynaptic neuromuscular junction (NMJ) dysfunction has been recently reported in 2 families harboring autosomal dominant pathogenic mutations in synaptotagmin 2 (SYT2).3,4 Here, we describe a new variant in SYT2 causing this same phenotype in a multigenerational family and present functional validation of a dominant-negative effect of the mutation on synaptic transmission in a Drosophila model.

Methods

Standard protocol approvals, registrations, and patient consents

Research-related activities were only performed after informed consent was obtained, as part of a University of Miami Institutional Review Board-approved project.

Clinical evaluation

The proband was evaluated at the Charcot-Marie-Tooth clinic at the University of Miami. Her initial assessment included a full history and physical examination. Disease severity was assessed using the Charcot-Marie-Tooth Neuropathy Score (CMTNS) version 2.5 Subsequent evaluation included electrophysiologic studies performed on a Cadwell Sierra Wave EMG machine, following standard protocols. Exercise facilitation was examined by performing a 10-second sustained contraction that was applied to the right abductor pollicis brevis (APB), abductor digiti minimi (ADM), and abductor hallucis (AH) muscles followed by stimulation over their respective motor nerves. Repetitive nerve stimulation (RNS) was performed on the right ulnar nerve recording at the ADM muscle. Ten supramaximal stimuli were applied at 3 Hz, with percentage increment or decrement calculated between the first and fourth response.

Amplification of SYT2 exons and Sanger sequencing

SYT2 sequence was obtained from University of California Santa Cruz genome browser to design amplification primers. Primers flanking each SYT2 exon were designed using Primer3 software. SYT2 exons were amplified from the proband’s and her mother’s genomic DNA by PCR with Platinum Taq polymerase (ThermoFisher). Amplifications were carried out in a thermal cycler (Applied Biosystem). PCR products were purified using Qiagen PCR purification kit. Each purified PCR product, corresponding to an exon, was submitted with corresponding sequencing primers to Eurofins for Sanger sequencing. Sequence traces were analyzed using Sequencher (Gene Codes, Ann Arbor, MI).

Following are the primers used for PCR and Sanger sequencing: SYT2-Ex1F: CTTGGTCTCTCCCTCCCCCCTCCT; SYT2-Ex1R: CCAACCCCTACCTACCTCCTCG; SYT2-Ex2F: GCCTGACTGTGTACTAATTGGATG; SYT2-Ex2R: CCCAGCTGAATCTTAAGCA; SYT2-Ex3F: CTCACCCA TTTTCCCCATG; SYT2-Ex3R: TTAAGGAGGGGAGCAGGTTT; SYT2-Ex4F: GTTCCACACACACACAGCTC; SYT2-Ex4R: GAGCTATAGGCCCTGCAGATT; SYT2-Ex5F: CATTCTTCCCCTGCCCAACT; SYT2-Ex5R: GCCATTTGTTCCAGGCTGAG; SYT2-Ex6F: TTGTGTCTGTCTCGGCACACT; SYT2-Ex6R: AGGCTGCTCTGCTTCCAAAG; SYT2-Ex7F: ACCCTTCGCGCCATCAATA; SYT2-Ex7R: GGCAGGAAATGTCCCTCCTT; SYT2-Ex8F: TGGTCTCAAGGGCTGAGG; SYT2-Ex8R: ACCCAAGGCCATGAGACT; SYT2-Ex9F: TGGGACA GAAGTAAACCAA; SYT2-Ex9R: CAGAGCAGGCTTCTC TCCCT.

Genetic screen and Drosophila stocks

Drosophila melanogaster was cultured on standard medium at 22°C. Transgenic strains were generated using standard microinjection into white (w−/−) embryos performed by BestGene Inc. UAS-syt1 transgenes were expressed using a GAL4 driver under the control of the pan-neuronal elav promoter, as previously described.6 DNA for rescue with individual point mutants was generated using the QuikChange multisite-directed mutagenesis kit (Stratagene, Santa Clare, CA) with the following primer sets: I426K-5′ oligo: GCCATTTGTTCCAGGCACACT; SYT2-Ex6R: ACCCTTCGCGCCATCAATA; SYT2-Ex7R: GGCAGGAAATGTCCCTCCTT; SYT2-Ex8F: TGGTCTCAAGGGCTGAGG; SYT2-Ex8R: ACCCAAGGCCATGAGACT; SYT2-Ex9F: TGGGACA GAAGTAAACCAA; SYT2-Ex9R: CAGAGCAGGCTTCTC TCCCT.

Wild-type and mutant complementary DNAs were subcloned into a modified pValum construct with an N-terminal myc tag to allow tracking of protein localization in overexpressed animals containing endogenous synaptotagmin 1 (SYT1). These constructs were injected into a yw; attP third chromosome docking strain by BestGene Inc. (Chino Hills, CA). All constructs allowed use of the Gal4/UAS expression system to express the transgenic proteins. UAS-Syt1 transgenes were expressed using a GAL4 driver under the control of the pan-neuronal C155 elav promoter in either control white or syt1 null (syt1−/−) backgrounds. Null mutants lacking endogenous SYT1 were generated by crossing Syt1AD4, which truncates SYT1 before the transmembrane domain,8 with Syt1AD4, which truncates SYT1 before the transmembrane domain.
anti-SYT1 (1:1,000, kindly provided by Noreen Reist) or anti-sytaxon (1:1,000, Developmental Studies Hybridoma Bank, Iowa City, IA). Visualization and quantification were done using a LI-COR Odyssey Imaging System (LI-COR Biosciences, Lincoln, MA). Immunostaining was performed on 3rd instar larvae at wandering stage larvae as described previously.9 Rabbit myc antibody (1:1,000; Genetex) and anti-horseradish peroxidase (1:1,000; Jackson ImmunoResearch, West Grove, PA) were used for immunostaining. Confocal stacks of muscle 6 and 7 NMJs containing immunoreactive proteins were captured on a Zeiss Pascal Confocal with PASCAL software (Carl Zeiss MicroImaging, Inc.) using a 63 x numerical aperture 1.3 Plan Neofluar oil immersion lens (Carl Zeiss, Inc) and fluorescent secondary antibodies (Molecular Probes, Carlsbad, CA).

Electrophysiology
Postsynaptic currents from third instar male larvae at the wandering stage from the indicated genotypes were recorded at muscle fiber 6 of segment A3 using 2-electrode voltage clamp with a ~80 mV holding potential in hemolymph-like (HL) 3.1 saline solution as previously described.6,10 Final calcium concentration was adjusted to 2 mM. For evoked and mini analysis, n refers to the number of NMJs analyzed, with no more than 2 NMJs analyzed per animal, and with animals derived from at least 3 independent experiments. Data acquisition and analysis was performed using Axoscope 9.0 and Clampfit 9.0 software (Molecular Devices, Sunnyvale, CA). Motor nerves innervating the musculature were severed and placed into a suction electrode, so action potential stimulation could be applied at the indicated frequencies using a programmable stimulator (Master8; AMPI, Jerusalem, Israel).

Data analysis and statistics
Electrophysiology analysis was performed using Clampfit 10 software (Axon Instruments, Foster City, CA), as previously described.9 Statistical analysis and graphs were performed using Origin Software (OriginLab Corporation, Northampton, MA). Statistical significance was determined using 1-way analysis of variance (ANOVA) (nonparametric) with post hoc Sidak multiple comparisons test. The p values associated with 1-way ANOVA tests were adjusted p values obtained from a post hoc Sidak multiple comparisons test. Appropriate sample size was determined using GraphPad Statmate. In all figures, the data are presented as mean ± SEM. Statistical comparisons are with control, unless noted. The results were all shown: N.S. = no significant change (p > 0.05), *p < 0.05, **p < 0.005, ***p < 0.0001, and ****p < 0.0001. All error bars are SEM.

Data availability
Data, methods, and materials used to conduct this research are documented in detail in the Methods section.

Results
Clinical evaluation
The Proband is a 50-year-old woman who was referred to the University of Miami Comprehensive CMT clinic for evaluation of suspected CMT because of gradually progressive weakness of her extremities. She had normal developmental milestones but was found to have bilateral high arched feet and hammertoes and occasional falls around the age of 8 years. She developed progressive leg weakness, worsening bilateral hand cramping, weak hand grip, and only mild paresthesia on distal extremities. The proband’s family history is remarkable for similar symptoms reported by her mother, maternal grandfather, 2 maternal uncles, 1 maternal aunt, a younger sister, and a nephew (figure 1A). Initial physical examination revealed bilateral pes cavus and hammer toes (figure 1B), inability to walk on heels or toes, severe, nonfatigable, distal lower extremity weakness, limited range of motion on ankles bilaterally because of ankle fusions, nonspecific sensory changes in lower extremities, and diffuse hyporeflexia with postexercise normalization. Her initial CMTNS was 9. Her mother, a 68-year-old woman, was also evaluated. She has had a history of high-arched feet and hammertoes since childhood. Examination showed bilateral pes cavus and hammer toes (figure 1B). Strength testing revealed intrinsic hand muscle and plantarflexion weakness. Deep tendon reflexes were absent initially, with postexercise facilitation noted. Sensory examination was essentially normal for touch, pinprick, vibration, and proprioception. Her CMTNS was 4.

Clinical neurophysiology testing
The proband underwent electrophysiological testing to further evaluate for a hereditary peripheral neuropathy. Sensory nerve conduction studies were normal. However, compound muscle action potential amplitudes were significantly reduced throughout all tested motor nerves. Examination of each motor nerve incidentally showed decreasing amplitudes with successive stimulations. For this reason, a 10-second sustained contraction was applied at the right abductor digiti minimi (ADM), APB, tibialis anterior, and AH, and their respective motor nerves were stimulated afterward. This resulted in significant incremental responses (figure 1C). RNS was subsequently performed on the right ulnar nerve recording at the right ADM and revealed a 42% decremental response and a 125% postexercise facilitation (figure 1, C and D). Needle EMG examination revealed evidence of ongoing denervation in the form of positive waves and fibrillation potentials and of chronic reinnervation in the form of reduced recruitment in the medial gastrocnemius muscles. The proband’s mother also underwent a limited nerve conduction studies and RNS examination with similar findings, including normal sural sensory response, 17.6% decremental response and an 86% postexercise facilitation on repetitive stimulation study (figure 1C). To rule out paraneoplastic Lambert-Eaton syndrome, the proband was investigated further and antibodies against voltage-gated calcium channel were negative, and a chest CT did not show evidence of lung carcinoma.

Genetic analysis
Sanger sequencing of the SYT2 gene revealed a heterozygous 1112T>A missense mutation in both the proband and her mother (figure 1E). This mutation causes an isoleucine (I) to
Figure 1 Clinical and genetic features of a family with Ile371Lys SYT2

(A) Family pedigree reveals multiple affected family members supporting autosomal dominant inheritance. Filled symbols are clinically affected individuals, arrow denotes the proband. (B) Both the proband and her mother presented long-standing pes cavus and hammer toes. (C) Table summarizing electrophysiologic findings for the proband and her mother. Main findings were significant postexercise facilitation in compound muscle action potential amplitudes, significant decremental response to 3 Hz repetitive stimulation, and normal sural sensory responses. (D) Graph summary of the proband’s repetitive stimulation study demonstrating both decremental response to 3 Hz repetitive stimulation and significant postexercise increment. (E) Sanger sequencing revealed a 1112T>A substitution in both the proband and her mother, resulting in an isoleucine (I) to lysine (K) change at residue 371. (F) This residue is highly conserved across species. ADM = abductor digiti minimi; amp = Amplitude; dCMAP = distal compound muscle action potential; N/A = not applicable; Rep. stim. = repetitive nerve stimulation; SNAP = sensory nerve action potential.
lysine (K) change at residue 371 (I371K). The I371K residue is located within the C2B domain of SYT2, which spans residues 271 to 406. This variant was not found in the Genome Aggregation Database (gnomAD). Further variant analysis using the PROVEAN (−2.643), SIFT (0.0), PolyPhen-2 (1.000), and Align-GVGD (Grantham variation [GV]: 0, Grantham deviation [GD]: 101.61, class: C65) scores predicted this variant to be disease causing. PhyloP (+4.83) and PhastCons (0.99) scores showed this variant to be highly conserved throughout different species (figure 1F).

**Functional validation of the new I371K SYT2 variant in Drosophila**

To examine how the I371K mutation affects synaptic transmission directly, we generated transgenic Drosophila expressing the mutant gene using the GAL4-UAS expression system. Drosophila has a single homolog (DSYT1) of the mammalian synaptic vesicle SYT subfamily that includes SYT1, SYT2, and SYT9. DSYT1 and human SYT2 share strong homology with conservation of the key residues that form the C2B calcium binding pocket, including I371 (corresponding to I426 in Drosophila) and 2 previous C2B residues that were found mutated in patients (D307 and P308, figure 2A). We generated wildtype (WT) and I371K UAS-Dsyt1 transgenic lines and expressed the transgenes in syt1−/− null mutants with the pan-neuronal GAL4 driver elav−/−. Drosophila Syt1−/− null mutants show a reduction in viability during larval development (50% survival to the 3rd instar stage) because of defective synaptic transmission. In contrast to the ability of WT SYT1 to rescue lethality (100% survival), SYT1 I426K not only failed to rescue but also caused a dramatic reduction in viability (2.9%) compared to null mutants alone (50%) (figure 2B). Western blot analysis indicated that the I426K SYT1 protein was expressed at similar levels to WT (figure 2C). Immunocytochemistry demonstrated that the protein also localized normally at NMJ synapses (figure 2D), suggesting the dominant effects on viability are secondary to aberrant function of SYT1 I426K versus degradation or abnormal localization. To analyze neurotransmitter release in Syt1 nulls that were rescued with either WT or I426K SYT1, we performed current recordings of postsynaptic responses in voltage-clamp at 3rd instar NMJs. As observed in the behavioral viability assays, I426K rescued animals displayed synaptic transmission defects that were worse than the Syt1 null mutant. I426K synapses displayed severely defective synchronous neurotransmitter release (figure 2E–G), a large increase in failure rate following stimulation (figure 2H) and enhancement of the slower asynchronous phase of release (figure 2I). I426K also failed to rescue the elevated rate of spontaneous fusion observed in Syt1 null mutants. These results indicate that the SYT1 I426K mutation eliminates the ability of the protein to drive calcium-triggered neurotransmitter release and acts dominantly to reduce the residual release that is normally observed in the absence of SYT1.

To model the dominant phenotype observed in patients that have one endogenous copy of WT SYT2, we characterized the effects of overexpressing I426K on synaptic transmission in the presence of endogenous DSYT1. Two independent transgenic insertions (1426K#1 and 1426K#2) were overexpressed using the elav−/− driver. Compared to overexpression of WT SYT1, both I426K lines resulted in a strong dominant-negative effect on action potential evoked release, decreasing the excitatory evoked functional current (eEJC) by 68.5% and 64.8%, respectively (figure 3, A and B). In addition, both I426K transgenic overexpression lines showed facilitation of the eEJC during 10 Hz stimulation compared to the synaptic depression observed in controls (figure 3, C and D), consistent with a reduction in the initial release probability caused by SYT1 I426K. These findings indicate that SYT I426K lacks normal function for promoting synaptic vesicle fusion and exerts a strong dominant-negative effect on synaptic transmission even in the presence of WT SYT1.

**Discussion**

Gain-of-function mutations in SYT2 have been recently associated with an autosomal dominant presynaptic congenital myasthenic syndrome in 2 families. SYT2 is an integral membrane protein of synaptic vesicles and serves as a calcium sensor for neurotransmitter release, with calcium binding to its C2B domain activating vesicle fusion.11–13 Of interest, the clinical presentation varied between families and family members, ranging from a presynaptic myasthenic disorder resembling Lambert-Eaton syndrome and a distal motor neuropathy, or even a combination of both. Here, we studied a multigenerational family with a new SYT2 mutation presenting with clear evidence of both presynaptic neuromuscular transmission impairment as well as a distal motor neuropathy, both clinically and electrophysiologically. This report therefore reinforces the link between SYT2 mutations and distal hereditary motor neuropathy.

Synaptotagmins 1 and 2 have been shown to have several major roles in regulating synaptic vesicle fusion. Their major function is as calcium sensors for driving fast synchronous fusion of synaptic vesicles at synapses. However, they also function to suppress the slower asynchronous fusion pathway, ensuring that release is tightly linked to the action potential. As such, in the absence of synaptotagmin 1, increased asynchronous release is observed because of loss of this suppression function. The I426K mutant disrupts the normal function of synaptotagmin 1, including its role in driving fast synchronous fusion, as well as its role in suppressing asynchronous release.

Synaptotagmin 1 null mutants die throughout development, with many dying during the larval stage. However, when placed directly on food where little movement is required, the animals can occasionally survive to adulthood, although they show severe motor defects. Similar to other species, including mammals, synaptotagmin 1 mutants still have residual slow neurotransmitter release. Although the identity of the residual “asynchronous” calcium sensor is still being debated, recent studies suggest that another member of the synaptotagmin family—synaptotagmin 7—may play this role.14,15 This explains the 50% survival observed in SYT null mutants.
Figure 2 I426K DSYT1 fails to rescue neurotransmitter release in synaptotagmin null mutants

(A) Stereoview of residues found to be mutated in human synaptotagmin 2 patients (Asp307 [orange], Pro308 [yellow], and Ile371 [red]) modeled on the rodent synaptotagmin 1 C2B crystal structure. The 5 essential calcium binding residues are highlighted in green and calcium ions in red. (B) The ability of transgenes to rescue the lethality of Syt1 null mutants is shown. Larvae were collected at the 1st instar larval stage and placed into food vials. The number of animals surviving to the 3rd instar wandering larval stage was quantified. Quantification of average rescue ratio (%) for the indicated genotypes (Syt1−/− null, 50.5 ± 6.9, n = 3; elavGAL4; Syt1−/−; UAS-SYT1, 100 ± 0, n = 3; elavGAL4; Syt1−/−; UAS-SYT1 I426K, 2.9 ± 2.9, n = 3). (C) Western blot with anti-MYC (top panel) or anti-syntaxin (SYX–control) antisera from head extracts of control or transgenic Drosophila: WT (control), WT DSYT or I426K DSYT induction by elavGAL4. (D) Representative larval NMJs stained with anti-MYC antisera (green) for animals with MYC-tagged WT or I426K SYT1. The axon is stained with the neuronal marker anti-HRP (blue). The boxed area is magnified in the bottom panel. Mutant SYT1 targets normally to presynaptic terminals. Scale bar—20 μM—top panels; 5 μM—bottom panels. (E) Representative eEJC recorded in 2 mM external calcium in Syt1−/− null larvae (red) and null mutants rescued with WT DSYT1 (blue) or I426K DSYT1 (green). (F) Quantification of mean eEJC amplitudes in the indicated genotypes: Syt1−/− null, 3.6 ± 0.5 nA, n = 15; elavGAL4; Syt1−/−; UAS-SYT1, 62.3 ± 10.6 nA, n = 15; elavGAL4; Syt1−/−; UAS-SYT1 I426K, 1.0 ± 0.2 nA, n = 15. (G) Expanded vertical axis scale of the data shown in (F). (H) Failure rates (%) as calculated by counting trials with no detectable eEJCs within 10 ms during 30 consecutive stimuli given at 0.5 Hz for the indicated genotypes: Syt1−/− null, 11.3 ± 3.4, n = 15; elavGAL4; Syt1−/−; UAS-SYT1, 0 ± 0, n = 15; elavGAL4; Syt1−/−; UAS-SYT1 I426K, 33.5 ± 4.0, n = 15. (I) Cumulative vesicle release defined by charge transfer normalized for the maximum in 2.0 mM calcium for each genotype (same color code as in E). Each trace was adjusted to a double exponential fit. Both the null and I426K rescued animals display a prominent increase in the slow asynchronous phase of release. (J) Quantification of mini frequency in the indicated genotypes: Syt1−/− null, 3.7 ± 0.3 Hz, n = 14; elavGAL4; Syt1−/−; UAS-SYT1, 1.7 ± 0.2 Hz, n = 14; elavGAL4; Syt1−/−; UAS-SYT1 I426K, 3.5 ± 0.5 Hz, n = 14. Statistical significance was determined using 1-way analysis of variance (nonparametric) with post hoc Sidak multiple comparisons test. N.S. = no significant change (p > 0.05), *p < 0.05, **p < 0.005, ***p < 0.001, and ****p < 0.0001. All error bars are SEM. eEJC = excitatory junctional current; HRP = horseradish peroxidase; NMJ = neuromuscular junction; WT = wildtype.
There is no known effect on localization of WT synaptotagmin 1 when the I426K mutant is co-expressed. Our work and others have indicated that multimerization of synaptotagmin 1 into oligomeric complexes is required for neurotransmitter release. Our current data indicate that the mutant I426K version forms mixed oligomers with WT synaptotagmin, and the loss of normal calcium binding by I426K poisons the multimeric complex that includes WT synaptotagmin, thus dramatically reducing neurotransmitter release and leading to the autosomal dominant phenotypes.

The role of NMJ impairment in the pathophysiology of inherited peripheral neuropathies has been the focus of several recent studies. NMJ transmission dysfunction is now well documented in several types of inherited neuropathies, including Congenital Hypomyelinating Neuropathy (PMP22 point mutations), CMT1B (PMPZ), CMT2D (GARS), and CMT2O (DNYC1H1). Findings include reduced size, branching, and complexity of NMJs by immunostaining studies, altered growth and maturation of the NMJs, reduced amplitudes of nerve-evoked muscle endplate potentials, and NMJ transmission failure during sustained nerve stimulation. In 2 different mouse models of CMT2D (GarsP278KY and GarsC201R), the NMJ deficits correlated with disease severity and progressed with age. These recent studies demonstrated that dysfunction and degeneration of NMJs are often an early pathologic finding even in primarily demyelinating inherited neuropathies and precede impairments in axonal conduction. Nevertheless, it is likely that, in this context, NMJ impairment is secondary to the distal, length-dependent axonal degeneration.

Figure 3 Overexpression of I426K DSYT1 dominantly disrupts neurotransmitter release

(A) Representative eEJC recorded in 2 mM extracellular calcium at 3rd instar larval muscle 6 NMJs for the indicated genotypes (control, overexpression of WT or I426K DSYT1 with elavC155-GAL4). (B) Quantification of mean eEJC amplitude in the indicated genotypes: control elavC155-GAL4, 293.3 ± 34.2 nA, n = 10; elavC155-GAL4; UAS-SYT1, 223.9 ± 11.7 nA, n = 12; elavC155-GAL4; UAS-SYT1 I426K#1, 92.4 ± 15.9 nA, n = 9; elavC155-GAL4; UAS-SYT1 I426K#2, 103.2 ± 12.2 nA, n = 10. (C) Representative eEJC during a 10 Hz tetanic nerve stimulation in 2 mM external calcium for the indicated genotypes. (D) The average eEJC for the first 10 responses normalized to the amplitude of the first response during a 10-Hz tetanus is shown for control (black), elavC155-GAL4; UAS-WT DSYT 1 (blue), elavC155-GAL4; UAS-DSYT1 I426K #1 (green) and elavC155-GAL4; and UAS-DSYT1 I426K #2 (magenta). Statistical significance was determined using 1-way analysis of variance (nonparametric) with post hoc Sidak multiple comparisons test. N.S. = no significant change (p > 0.05), ***p < 0.001, ****p < 0.0001. All error bars are SEM. eEJC = excitatory junctional current; NMJ = neuromuscular junction.
process characteristic of most types of inherited neuropathies and not directly linked to specific presynaptic transmission dysfunction. Of note, no electrophysiologic evidence of presynaptic NMJ transmission has been previously reported in patients with CMT.

This concept was challenged recently by the identification of mutations in the presynaptic choline transporter SLC5A7 as a cause of distal hereditary motor neuropathy type VII (dHMN VII). SLC5A7 is a Na+/Cl−-dependent high-affinity transporter that mediates uptake of choline for acetylcholine synthesis and therefore is a critical determinant of presynaptic acetylcholine synthesis and release at the NMJ. Of interest, as is the case for SYT2 mutations, patients with dHMN VII do not present the hallmark clinical features of a congenital myasthenic syndrome, namely, ophthalmoparesis, ptosis, bulbar weakness, and respiratory fatigable weakness. Nonetheless, the role of these 2 presynaptic NMJ proteins in the etiology of hereditary motor neuropathies provides a new framework to investigate the connections between NMJ transmission and axonal biology and function.

The clinical findings in our patients are in keeping with the phenotype described in 2 families with SYT2 mutations, including foot deformities since childhood, distal weakness, minimal sensory findings, and reduced deep tendon reflexes with evidence of postexercise facilitation. The electrodiagnostic features were also in agreement with the previous report, demonstrating clear presynaptic neuromuscular transmission dysfunction characterized by decremental response to RNS and significant postexercise facilitation and normal sensory responses. We identified a new SYT2 mutation causing autosomal dominant distal hereditary motor neuropathy, confirming the interesting connection between presynaptic neuromuscular transmission dysfunction and motor axonopathy.

Study funding
No targeted funding reported.

Disclosure
N.I. Montes-Chinea, Z. Guan, M. Coutts, C. Vidal, S. Courel, A.P. Rebelo, L. Abreu, and S. Zuchner report no disclosures. J. T. Littleton has received research support from NIH. M.A. Saporta has served on scientific advisory boards for the Charcot-Marie-Tooth Association and Acceleron; serves on the editorial board of the Journal of the Peripheral Nervous System; has been a consultant for Anylam, Strongbridge, Biogen, and Serepta; and has received research support from the Charcot-Marie-Tooth Association. Full disclosure form information provided by the authors is available with the full text of this article at Neurology.org/NG.

Received June 11, 2018. Accepted in final form August 21, 2018.

References
### Appendix 1 Author contributions

<table>
<thead>
<tr>
<th>Name</th>
<th>Location</th>
<th>Role</th>
<th>Contribution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nataly I. Montes-Chinea, MD</td>
<td>University of Miami, Miami</td>
<td>Author</td>
<td>Major role in the acquisition of data, design and conceptualized study; analyzed the data; drafted the manuscript for intellectual content.</td>
</tr>
<tr>
<td>Zhuo Guan, PhD</td>
<td>Massachusetts Institute of Technology</td>
<td>Author</td>
<td>Major role in the acquisition of data.</td>
</tr>
<tr>
<td>Marcella Coutts, MD</td>
<td>University of Miami, Miami</td>
<td>Author</td>
<td>Major role in the acquisition of data.</td>
</tr>
<tr>
<td>Cecilia Vidal, MD</td>
<td>University of Miami, Miami</td>
<td>Author</td>
<td>Major role in the acquisition of data.</td>
</tr>
<tr>
<td>Steve Courel</td>
<td>University of Miami, Miami</td>
<td>Author</td>
<td>Major role in the acquisition of data; analyzed the data.</td>
</tr>
<tr>
<td>Adriana P. Rebelo, PhD</td>
<td>University of Miami, Miami</td>
<td>Author</td>
<td>Major role in the acquisition of data; analyzed the data; drafted the manuscript for intellectual content.</td>
</tr>
<tr>
<td>Lisa Abreu</td>
<td>University of Miami, Miami</td>
<td>Author</td>
<td>Major role in the acquisition of data.</td>
</tr>
<tr>
<td>Stephan Zuchner</td>
<td>University of Miami, Miami</td>
<td>Author</td>
<td>Drafted the manuscript for intellectual content.</td>
</tr>
<tr>
<td>J.Troy Littleton</td>
<td>Massachusetts Institute of Technology</td>
<td>Author</td>
<td>Design and conceptualized study; analyzed the data; drafted the manuscript for intellectual content.</td>
</tr>
<tr>
<td>Mario A. Saporta, MD, PhD, FAAN</td>
<td>University of Miami, Miami</td>
<td>Corresponding author</td>
<td>Major role in the acquisition of data, design and conceptualized study; analyzed the data; drafted the manuscript for intellectual content.</td>
</tr>
</tbody>
</table>

Identification of a new SYT2 variant validates an unusual distal motor neuropathy phenotype
Nataly I. Montes-Chinea, Zhuo Guan, Marcella Coutts, et al.

Neurol Genet 2018;4;
DOI 10.1212/NXG.0000000000000282

This information is current as of October 22, 2018